|Dr. Gary L. Wilcox||Co-Founder, Chairman & CEO||136.95k||N/A||1947|
|Dr. Sam Lee||Co-Founder & Pres||200.84k||N/A||1960|
|Mr. James J. Martin CPA, M.B.A., CPA, MBA||CFO & Corp. Sec.||230.84k||N/A||1967|
|Dr. Roger D. Kornberg||Co-Founder, Chairman of Scientific Advisory Board & Chief Scientist||N/A||N/A||1947|
Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of various antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza. It is also involved in identifying and developing various non-nucleoside polymerase inhibitors for norovirus gastroenteritis. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck & Co., Inc. to discover and develop proprietary influenza A/B antiviral agents; and a collaboration agreement National Institute of Health. The company was founded in 2007 and is headquartered in Tucker, Georgia.
Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.